112 related articles for article (PubMed ID: 8546464)
1. [Dynamics of photosensitizer in the cell].
Aizawa K; Kuroiwa Y; Tsuchida T; Xiahedin I; Shibuya H; Saito K
Gan To Kagaku Ryoho; 1996 Jan; 23(1):22-6. PubMed ID: 8546464
[TBL] [Abstract][Full Text] [Related]
2. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
3. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
7. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
8. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6).
Mori K; Yoneya S; Ohta M; Sano A; Anzai K; Peyman GA; Moshfeghi DM
Ophthalmology; 1999 Jul; 106(7):1384-91. PubMed ID: 10406627
[TBL] [Abstract][Full Text] [Related]
9. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
10. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
11. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice.
Thomas N; Tirand L; Chatelut E; Plénat F; Frochot C; Dodeller M; Guillemin F; Barberi-Heyob M
Photochem Photobiol Sci; 2008 Apr; 7(4):433-41. PubMed ID: 18385885
[TBL] [Abstract][Full Text] [Related]
12. Talaporfin: LS 11, LS11, ME 2906, mono-L-aspartyl chlorin e6, NP e6, NPE 6, taporfin sodium.
Drugs R D; 2003; 4(1):69-71. PubMed ID: 12568643
[No Abstract] [Full Text] [Related]
13. Chlorin e6 combined with albumin nanoparticles as a potential composite photosensitizer for photodynamic therapy of tumors.
Shton IO; Sarnatskaya VV; Prokopenko IV; Gamaleia NF
Exp Oncol; 2015 Dec; 37(4):250-4. PubMed ID: 26710836
[TBL] [Abstract][Full Text] [Related]
14. [A basic study of photodynamic therapy of experimental hepatoma with ME 2906].
Nakamura J; Kajiwara H; Nakamura M; Watanabe M; Naganuma K; Tanaka H; Usui S; Sumiyama Y; Saito K; Aizawa K
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1454-6. PubMed ID: 9703852
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy using mono-L-aspartyl chlorin e6 for rabbit experimental hepatoma.
Nakamura J; Kajiwara H
J Hepatobiliary Pancreat Surg; 1999; 6(3):312-9. PubMed ID: 10526068
[TBL] [Abstract][Full Text] [Related]
17. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
Mori K; Ohta M; Sano A; Yoneya S; Sonoda M; Kaneda A; Sato Y
Nippon Ganka Gakkai Zasshi; 1997 Feb; 101(2):134-40. PubMed ID: 9124093
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
Nelson JS; Roberts WG; Berns MW
Cancer Res; 1987 Sep; 47(17):4681-5. PubMed ID: 2957047
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of Radachlorin(R) sensitizer for photodynamic therapy.
Douillard S; Olivier D; Patrice T
Photochem Photobiol Sci; 2009 Mar; 8(3):405-13. PubMed ID: 19255683
[TBL] [Abstract][Full Text] [Related]
20. Mono-(L)-aspartylchlorin-e6.
Hargus JA; Fronczek FR; Vicente MG; Smith KM
Photochem Photobiol; 2007; 83(5):1006-15. PubMed ID: 17880493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
